Название продукции:(1-ethoxycyclopropoxy)trimethylsilane
IUPAC Name:(1-ethoxycyclopropoxy)trimethylsilane
- CAS:27374-25-0
- Молекулярная формула:C8H18O2Si
- Чистота:95%+
- Номер в каталоге:CM111264
- Молекулярная масса:174.32
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:27374-25-0
- Молекулярная формула:C8H18O2Si
- Точка плавления:-
- Smiles-код:C[Si](C)(OC1(OCC)CC1)C
- Плотность:
- Номер в каталоге:CM111264
- Молекулярная масса:174.32
- Точка кипения:
- Номер Mdl:MFCD00074986
- Хранение:
Category Infos
- Cyclopropanes
- Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.
Column Infos
- Silane Compounds
- Silanes are a series of silicon substitutes for carbon alkanes, which consisting of multiple silicon atoms linked to each other as the main chain and hydrogen atoms or other chemical elements linked with the main chain. Silanes are versatile chemicals used in the modification of SPR sensor surfaces. In particular, the silane molecules, such as 3-mercaptopropyl trimethoxy silane, are convenient for use as linkers in surface modification of SPR sensors.
- JNT-517
- Jnana Therapeutics announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, is being evaluated as a potential first-in-class oral treatment for PKU across all ages and genotypes. Based on these positive mid-term results, Jnana has adjusted its phase 1b clinical trial design to support the critical phase 3 clinical trial of JNT-517 starting in the first half of 2025.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.